Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00242424 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age
A Phase 2 study of Inactivated Influenza Vaccine, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,375
- Enrollment target
- 1
- Study location
NCT00242424: Completed Phase 2 study of Inactivated Influenza Vaccine, sponsored by Seattle Children's Hospital.
NCT00242424 is a Phase 2 study of Inactivated Influenza Vaccine that has completed, run by Seattle Children's Hospital. The registered enrollment target is 1,375 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (934% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00242424, a Phase 2 study of Inactivated Influenza Vaccine, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,375 participants
- Enrollment target
- 1
- Study location
Study Summary
Study of the safety and immunogenicity (antibody producing capability) comparing inactivated influenza vaccine to placebo given to infants at 2 and 3 months of age. Infants will receive inactivated influenza vaccine at the same time as other vaccines on the routine immunization schedule. Infants will be randomized at enrollment to receive inactivated influenza vaccine or placebo at a 2:1 ratio. This study is double-blind, randomized, and placebo-controlled.
Conditions Studied
Interventions
- BIOLOGICAL 2005-2006 trivalent inactivated influenza vaccine
Study Locations (1)
Washington
- Seattle Children's Hospital and Regional Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,375 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
What the finished NCT00242424 record still lists
NCT00242424 is an interventional study that assigns participants to a tested intervention. Its 1,375 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (934% higher).
The record links to 1 condition, with Inactivated Influenza Vaccine appearing as the primary indexed condition, and to 1 intervention - of which 2005-2006 trivalent inactivated influenza vaccine is the first listed.
NCT00242424 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00242424 about?
NCT00242424 is a clinical study titled "Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age". Study of the safety and immunogenicity (antibody producing capability) comparing inactivated influenza vaccine to placebo given to infants at 2 and 3 months of age. Infants will receive inactivated influenza vaccine at the same time as other vaccines on the routine immunization schedule. Infants wil...
What is the current status of trial NCT00242424?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,375 participants. The study started on 2005-09. Estimated completion is 2007-09.
What conditions does trial NCT00242424 study?
This clinical trial studies the following conditions: Inactivated Influenza Vaccine.
What interventions are being tested in trial NCT00242424?
The interventions under investigation include: 2005-2006 trivalent inactivated influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00242424?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00242424 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00242424's enrollment target sits among peer trials
1,375 13th of 2000 higher than 1,988 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06651281 · 1,380 participants · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT02677064 · 1,365 participants
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia